Bemarituzumab
20210104
Phase 2 small_molecule active
Quick answer
Bemarituzumab for Solid tumours is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Solid tumours
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active